Peritumoral and intratumoral materials for cancer therapy
AssigneePresident and Fellows of Harvard College
InventorsKoshy T. Sandeep, David J. Mooney
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions for reducing tumor-mediated immune evasion and inducing patient-specific immunization.
Claims47
A method of reducing tumor-mediated immune evasion comprising administering to a tumor site a biodegradable porous polymeric device comprising (a) an inhibitor of T cell or dendritic cell suppression or (b) an immunostimulatory compound, wherein said device lacks a tumor antigen prior to administration to a subject.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
25-39. (canceled)
(canceled)
(canceled)
(canceled)
A method of treating a subject afflicted with a tumor, comprising administering to a tumor site a biodegradable porous polymeric device comprising (a) an inhibitor of T cell or dendritic cell suppression or (b) and immunostimulatory compound, wherein said device lacks a tumor antigen prior to administration to a subject.
(canceled)
50-58. (canceled)
(canceled)
(canceled)
A biodegradable porous polymeric device comprising at least two of
- (a) a compound that induces immunogenic cell death of a tumor cell;
- (b) a compound that attracts an immune cell to or into the device;
- (c) an immunostimulatory compound;
- and
- (d) a compound that inhibits tumor-mediated T cell or dendritic cell suppression.
65-74. (canceled)
(canceled)
78-79. (canceled)
Dependencies are inferred from the claim text.